Biodexa's 1H26 Results Highlight Cash Runway to Q4 2026 and Going Concern Uncertainty
BDRX has more than doubled off its 52-week low of $0.61 on elevated volume (52× avg).
Summary
Biodexa's 1H26 results show a £1.84 million loss, £3.23 million cash balance, and a going concern warning with further financing needed by Q4 2026. The company also faces potential Nasdaq delisting risk.
Updates
· SEC 424B3 — The 424B3 prospectus supplement incorporates the 6-K and notes the last reported closing price of ADSs on September 10, 2026 was $0.6676.
Key Events · Earnings and Guidance · BDRX
-
Going Concern Material Uncertainty
Directors state further financing will be required during Q4 2026; cash balance of £3.23 million at June 30, 2026, plus $3.5 million raised July 1, 2026, provides only a short runway.
-
Nasdaq Listing Risk
Company's market capitalization is below Nasdaq's proposed $5 million minimum threshold; implementation stayed pending SEC review, but non-compliance could limit financing and strategic options.
-
1H26 Financial Results
Consolidated loss of £1.84 million (1H25: £3.81 million); R&D costs rose 75% to £2.92 million; net cash used in operating activities was £4.61 million.
-
Serenta Phase 3 Enrollment Progress
92 of 168 planned subjects enrolled across 19 US and 10 European centers; two Canadian centers expected to begin enrolling in 4Q26.
Analysis · BDRX · Life Sciences
The interim results from Biodexa lay bare a critical cash position: £3.23 million at June 30, 2026, with management stating further financing will be required during Q4 2026. The going concern material uncertainty is the dominant issue — the company's ability to continue as a going concern depends on raising capital within months. The July 1, 2026 fundraise of $3.5 million provides only a short bridge. The company also flags that its market capitalization is below Nasdaq's proposed $5 million minimum threshold, adding listing risk. On the operational side, the Serenta Phase 3 trial is 55% enrolled (92 of 168 subjects), and the MTX240 in-license adds a new GIST asset, but these positives are overshadowed by the financing cliff.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 49.5% of the 190 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $679.3K. The 52-week trading range was $0.61 to $59.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.